One clear path forward is to build consortia to aggregate data across many studies for genetic association analyses. Genetic association consortia have worked for medical disease, psychiatric traits, and normal range behaviors. They guarantee increased power through increased sample size and, when successful, they provide many new opportunities for additional analyses and hypotheses that cannot be answered in a single dataset. Consortia are also one way in the current funding climate to obtain genotyping funds. There are many studies with electrophysiological data but not genome-wide genotypes. By banding together and building total sample size into the tens of thousands it may become feasible to request funding to genotype all available non-genotyped samples because, once done, there is reason to think a genetic association study of the large sample would be successful. This particular approach has been successful in funding genotyping in the Psychiatric Genomics Consortium (PGC; Sullivan, 2010). PGC comprises consortia to study the genetics of many disorders in addition to schizophrenia, such as autism, ADHD, substance abuse, major depressive disorder, bipolar disorder, PTSD, OCD, and anorexia nervosa (https://www.med.unc.edu/pgc). There
